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associated with early improvement in LVEF following TAVR, sug-
gesting the existence of undetectable LV functional differences by
conventional echocardiographic parameters. Detailed LV assessment
with strain echocardiography as well as conventional echocardiogra-
phy may help predict the LV functional recovery after TAVR.
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BACKGROUND The release of cardiac biomarkers of myocardial injury
after transcatheter aortic valve replacement (TAVR) is common, but
no data exist on those patients undergoing TAVR through transaortic
approach. We aimed to evaluate the incidence and prognostic signif-
icance of the increase in cardiac biomarkers in non-transfemoral TAVR
candidates, comparing transaortic and transapical approaches.
METHODS After excluding patients deemed unsuitable for trans-
femoral TAVR, 251 consecutive patients (transaortic¼45; trans-
apical¼206) were prospectively evaluated. Creatine kinase-MB (CK-
MB) and cardiac troponin T (cTnT) levels were measured at baseline
and at 6-12,24,48, and 72 hours following TAVR. Baseline and 6-12
month echocardiographic and clinical follow-up were performed.
Patients were analyzed overall and also matched using a propensity
score matching (1:2).
RESULTS Following TAVR, cTnT increased above the upper normal
values in all patients (peak value: 0.64mg/l[IQR: 0.39-1.03mg/l]),
whereas CK-MB levels increased in 88% of patients (transaortic:51%,
transapical:96%,p<0.001; peak value: 20.1mg/l[IQR: 14.3-31.6mg/l]).
Compared with the transaortic approach, transapical approach was
associated with a greater rise in both cardiac biomarkers (p<0.001 for
both), and a lesser improvement in left ventricular ejection (p¼0.058)
and global longitudinal strain (p¼0.039) at 6-12-month follow-up.
These results were also consistent for the propensity matched scoreanalysis (transaortic¼37; transapical¼65). Importantly, greater in-
creases of cTnT levels independently associated with 30-day and 1-
year overall and cardiovascular mortality (p<0.001 for all). A 15-fold
rise in cTnT levels was the optimal threshold for determining poorer
outcomes (p<0.001).
CONCLUSIONS Peri-procedural TAVR-related myocardial injury in
non-transfemoral candidates was demonstrated in all patients, but
transapical approach was associated with signiﬁcantly greater
myocardial injury compared with transaortic approach. A higher de-
gree of myocardial injury translated into reduced left ventricular
function improvement and lower early- and mid-term survival rates.
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BACKGROUND Cardiac biomarker release signifying myocardial
injury after transcatheter aortic valve replacement (TAVR) is common,
yet its clinical impact within a large TAVR population receiving
differing types of valve and procedural approaches is unknown. This
precluded a validation of the most appropriate biochemical threshold
for deﬁning clinically relevant myocardial infarction post-TAVR. The
objectives were to determine, in a large cohort of patients undergoing
TAVR, the incidence, clinical impact and factors associated with car-
diac biomarker elevation post-TAVR.
METHODS This multicenter study included 1,131 consecutive patients
undergoing TAVR with balloon- (58%) or self-expandable (42%)
valves. Transfemoral, transapical (TA), transaortic and trans-subcla-
vian approaches were selected in 73.1%, 20.3%, 4.2% and 2.3% of the
patients, respectively. Creatine kinase-MB (CK-MB) measurements
were obtained at baseline and at several time points within the initial
72 hours post-TAVR. Echocardiography was performed at baseline and
at 6- to 12-month follow-up.
RESULTS Overall, 66% of the TAVR population demonstrated some
degree of myocardial injury as determined by a rise in CK-MB levels
[peak value (IQR): 1.6-fold (0.9 to 2.8-fold)]. TA approach was inde-
pendently associated with higher peak of CK-MB levels (p <0.001),
